Low-Dose Versus Standard-Dose Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multicenter Randomized Phase III Trial The Systemic Therapy in Advancing or Metastatic ...
Advanced digital pathology and biopsy analysis are used to identify patients who benefit from intensified prostate cancer treatment. The STAMPEDE trial demonstrated that adding Zytiga to standard ...
Dr Petros Grivas surveys several exciting developments in prostate cancer research, including AI-driven biomarker analysis from the STAMPEDE trial, to identify high-risk patients who may benefit from ...
Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results